Search
Ipilimumab
go.drugbank.com/drugs/DB06186ApprovedInvestigationalIpilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). … [L12126] Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Categories: Immunoglobulin G, CTLA-4-directed Blocking AntibodyProducts: YERVOY®5 MG /ML SOLUCION INYECTABLE PARA INFUSION INTRAVENOSA, YERVOY 5 mg/ml concentrate for solution for infusionIGN101
go.drugbank.com/drugs/DB06500ExperimentalIt consists of 500 ug 17-1A antibody adsorbed on aluminum hydroxide.
Ketamine
go.drugbank.com/drugs/DB01221ApprovedInvestigationalVet approvedKetamine is an NMDA receptor antagonist with a potent anesthetic effect.[A31869] It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories.
Categories: Cytochrome P-450 Substrates, N-Methylaspartate, agonistsSynonyms: 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone, 2-(methylamino)-2-(2-chlorophenyl)cyclohexanoneLY-517717
go.drugbank.com/drugs/DB05713InvestigationalLY517717 is an investigational oral direct inhibitor of activated Factor Xa. It is believed to be Lilly's PMD-3112 (licensed from Amgen).
Categories: Heterocyclic Compounds, 1-RingObicetrapib
go.drugbank.com/drugs/DB14890InvestigationalObicetrapib is under investigation in clinical trial NCT02241772 (A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)).
Categories: Heterocyclic Compounds, 2-RingLedipasvir
go.drugbank.com/drugs/DB09027ApprovedIt is effective against genotypes 1a, 1b, 4a, and 5a and with a lesser activity against genotypes 2a and 3a of HCV. … therapy option in combination with [sofosbuvir] for the treatment of HCV genotypes 1a, 1b, 4, 5, and 6 [L852].
Mixtures: HARVONI®Categories: P-glycoprotein inhibitors, P-glycoprotein substratesNirmatrelvir
go.drugbank.com/drugs/DB16691ApprovedInvestigational[L33354] 3CL<sup>PRO</sup> is responsible for cleaving polyproteins 1a and 1ab of SARS-CoV-2. … [L33359] In December 2021, the FDA granted an emergency use authorization to Paxlovid, a co-packaged product containing both nirmatrelvir and [ritonavir], for the treatment of certain patients with
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesVilobelimab
go.drugbank.com/drugs/DB16416ApprovedInvestigationalVilobelimab is a chimeric monoclonal immunoglobulin G4 (IgG4) antibody that binds to the soluble form of human C5a with high affinity. … It consists of mouse anti-human complement factor 5a (C5a) monoclonal binding sites (variable regions of heavy and light chain regions) and human gamma 4 heavy chain and light kappa chain constant regions
Synonyms: IFX-1Tilmanocept
go.drugbank.com/drugs/DB15373ApprovedInvestigationalWithdrawnTilmanocept is under investigation in clinical trial NCT03241446 (Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed … With Rheumatoid Arthritis (RA)).
Iopydone
go.drugbank.com/drugs/DB20831ApprovedWithdrawnIopydone is a small molecule drug. Iopydone has a monoisotopic molecular weight of 346.83 Da.
Categories: Heterocyclic Compounds, 1-RingSynonyms: 3,5-diiodo-4(1h)-pyridone